Y Intercept Hong Kong Ltd Makes New $287,000 Investment in Galectin Therapeutics Inc. (NASDAQ:GALT)

Y Intercept Hong Kong Ltd purchased a new stake in Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 235,192 shares of the company's stock, valued at approximately $287,000. Y Intercept Hong Kong Ltd owned approximately 0.37% of Galectin Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Geode Capital Management LLC grew its stake in Galectin Therapeutics by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 870,589 shares of the company's stock worth $1,124,000 after buying an additional 8,047 shares in the last quarter. Northern Trust Corp grew its stake in Galectin Therapeutics by 4.3% during the fourth quarter. Northern Trust Corp now owns 244,274 shares of the company's stock worth $315,000 after buying an additional 9,994 shares in the last quarter. Sovran Advisors LLC grew its stake in Galectin Therapeutics by 7.4% during the first quarter. Sovran Advisors LLC now owns 199,830 shares of the company's stock worth $244,000 after buying an additional 13,816 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in Galectin Therapeutics by 46.8% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 51,510 shares of the company's stock worth $66,000 after buying an additional 16,412 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in Galectin Therapeutics by 101.4% during the fourth quarter. Bank of America Corp DE now owns 38,358 shares of the company's stock worth $49,000 after buying an additional 19,316 shares in the last quarter. 11.68% of the stock is currently owned by institutional investors and hedge funds.

Galectin Therapeutics Price Performance

NASDAQ GALT traded up $0.01 during trading hours on Friday, reaching $3.65. The company's stock had a trading volume of 294,650 shares, compared to its average volume of 326,806. The firm has a fifty day simple moving average of $2.25 and a 200-day simple moving average of $1.69. The stock has a market cap of $231.02 million, a P/E ratio of -5.07 and a beta of 0.70. Galectin Therapeutics Inc. has a 52 week low of $0.73 and a 52 week high of $3.90.

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.05. On average, research analysts expect that Galectin Therapeutics Inc. will post -0.73 earnings per share for the current year.

Wall Street Analysts Forecast Growth

GALT has been the topic of a number of research analyst reports. HC Wainwright initiated coverage on shares of Galectin Therapeutics in a research note on Tuesday, June 17th. They issued a "buy" rating and a $6.00 price target on the stock. Wall Street Zen upgraded shares of Galectin Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, June 21st.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.